BioNJ welcomes BioMatters, Inc., and HDL Apomics as new Core Members for 2012.
Biomatters, Inc., develops and markets Geneious Pro, a revolutionary bioinformatics software platform that is both ultra-powerful and easy to use. Scientists, researchers, and students are able to search, organize, and analyze genomic and protein information via a single desktop program that provides publication-ready images that enhance the impact of their research.
Complex data such as entire bacterial genomes or human chromosomes can be stored, visualized, and analyzed using a single application that unites pipelines and tools to ensure analyses are easily repeatable.
A companion product, Geneious Server, is a powerful software package designed specifically for highly intensive scientific computing.
HDL Apomics is taking a high-density lipoprotein (HDL)–centric view as the basis for progressing our understanding of cardiovascular disease and its associated complications through risk profiling based on measuring the dynamic status of an individual’s HDL particle population. Currently in development, our multiplex antibody array will generate a high-definition “HDL fingerprint” directly from plasma. Fingerprint matching against our genetic and disease-state sample library enables assessment of cardiovascular disease and through proprietary analytics will develop validated biomarkers for diagnosis, risk assessment, and response to therapy. HDL Apomics will offer diagnostic services to the biotechnology and pharmaceutical industries to markedly improve success rates in clinical trials and reduce time to market, ultimately affording improved quality of patient care.
BioNJ welcomes Acumen BioPharma, Berry & Company Public Relations, Integrated Resources, Inc., Navigant Consulting, and PharmApprove as new Associate Members for 2012.
Acumen BioPharma is a one-stop biopharmaceutical expert-witness services providing intellectual property law firms and the biopharmaceutical industry with the scientific foundation to build the winning argument regarding patent infringement. Our services include:
- Leading academics with stellar scientific credentials and experience as expert witnesses
- Measurement and Characterization services providing unparalleled access to academic laboratories equipped with state-of-the-art equipment and modeling methodologies for process and material characterization
- Literature searches and deep scientific evaluation to back up infringement/non-infringement position
We deliver reliable, timely services utilizing respected scientific experts with absolute integrity.
Berry & Company Public Relations was founded in 1993 in Manhattan and specializes in healthcare. Our team develops public relations strategies that connect our clients to the audiences they need to reach. We focus primarily on pharmaceuticals, biotechnology, diagnostics, and medical and surgical devices, and we develop programs for products from pre-clinical to post-launch. We develop campaigns that target patients, clinicians, laboratory teams, researchers, the surgical suite, and the public. We regularly work to promote advances in clinical research and have experience in most therapeutic areas including cardiovascular disease, oncology, immune disorders, genetic disease, reproductive medicine, diagnostics, and all forms of surgery.
Integrated Resources, Inc., (IRI) is a premier staffing firm recognized as one of the tri-state’s most well-respected professional specialty firms. IRI has built its reputation on excellent service and integrity since its inception in 1996. Our mission centers on delivering only the best quality talent, the first time and every time. We provide quality resources in four specialty areas: Information Technology (IT), Clinical Research, Rehabilitation Therapy, and Nursing.
Navigant Consulting’s Life Sciences Strategy Practice is a global strategy consulting practice serving pharmaceutical, biotechnology, and medical device companies. We have established a reputation as a trusted partner for life science companies. Clients retain us because we provide a unique combination of industry and scientific knowledge, global and regional perspectives, and superior analytical and consulting capabilities. We offer expertise in multiple therapeutic areas; have the ability to gather key insights from physicians, providers, patients, and payers; and have developed capabilities tailored to meet the needs of the life sciences industry.
PharmApprove is a strategic communications consulting firm that helps drug and device development teams prepare and deliver their product’s key messages at critical, high-profile regulatory events in both the United States and Europe. Over the past 10 years, PharmApprove has led over 50 Advisory committee preparation projects, and this is the primary focus of our business. By working intensively with team members as well as with the material they will present, PharmApprove helps sharpen the product message and enhance each team member’s ability to speak clearly, argue persuasively, negotiate effectively, and answer questions decisively in virtually any regulatory setting.
The firm offers a comprehensive range of services covering every aspect of hearing preparation. Those services include strategy and message development; briefing package and presentation development; slide composition; organization and retrieval; Q&A development and management; speaker, bullpen, and media training; project management; mock panel production; and onsite services.
PharmApprove was established in 1999 as a division of Taft and Partners, an integrated communications agency based in Princeton, NJ, that specializes in high-profile presentations and communications in other industries. As necessary, PharmApprove “borrows” expertise from Taft – including public relations, public affairs, video production, and media training – to augment its offerings in hearing preparation.
In addition to our primary business of hearing preparation, we have experience with other product strategy and communications initiatives. We also facilitate “lessons learned” retreats and global meetings, and we train executives in one-on-one presentation and Q&A skills sessions.
BioNJ thanks Platinum Members EisnerAmper and Pfizer for renewing their Memberships for 2012.
The 30+ professionals of the EisnerAmper Life Sciences Group understand the issues that are important to companies operating in this exciting space, including internal controls, financing and capitalization issues, research and development tax credits, and revenue recognition. The professionals represent a cross-section of specialties, from accounting, audit, and tax to internal audit and government contract accounting, serving over 150 private and public companies.
Pfizer Inc: Working together for a healthier world™
At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety, and value in the discovery, development, and manufacturing of medicines for people and animals. Our diversified global healthcare portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world’s best-known consumer products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments, and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world’s leading biopharmaceutical company, we also collaborate with healthcare providers, governments, and local communities to support and expand access to reliable, affordable healthcare around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more about our commitments, please visit our website.
BioNJ thanks Platinum Members PricewaterhouseCoopers LLP and SNR Denton for renewing their Memberships for 2011.
PricewaterhouseCoopers LLP (“PwC”), the world’s largest professional services organization, helps its clients build value, manage risk, and improve their performance. Drawing on the talents of nearly 8,000 partners in 148 countries, PwC provides a full range of business advisory services.
SNR Denton’s Venture Technology practice, a top-10 law practice for venture capital transactions in the United States, provides nimble, fast-paced counsel to cutting-edge emerging growth companies and venture-capital firms — from Silicon Valley to New York to London and around the globe. Our multidisciplinary team of lawyers operates at the convergence of innovation, strategy, finance, and law. We leverage deep expertise in life sciences, medical devices, media and entertainment, telecommunications, cleantech, and health information technology, along with a global network of venture-capital and investment-banking relationships, to remove hurdles to our clients’ success.
BioNJ thanks our Core Members who have renewed their Memberships for 2012.
Agile Therapeutics is a specialty pharmaceutical company focused on developing and commercializing innovative women’s healthcare products that address unmet needs. Agile was founded in 1997 and is headquartered in Princeton.
Amgen is a leading human therapeutics company in the biotechnology industry. For more than 25 years, the company has tapped the power of scientific discovery and innovation to advance the practice of medicine. Amgen pioneered the development of novel products based on advances in recombinant DNA and molecular biology and launched the biotechnology industry’s first blockbuster medicines.
Bezwada Biomedical LLC is an innovation-driven startup company catering to the unmet needs of the biomaterial community and medical device industry. With our state-of-the-art research and development facilities in the United States and India, combined with our platform technologies derived from a family of novel and proprietary biodegradable polymeric biomaterials, we work with and for our customers to translate their demands into high-quality products for a wide range of medical device and therapeutic applications in a cost-effective manner. Our expertise lies in the area of absorbable polyurethane, absorbable polymers derived from functionalized natural products, drug molecules and amino acids, adhesion prevention barriers, absorbable drug-eluting stent coatings, tissue adhesive and sealant, medical device coatings, drug delivery, drug device combination, absorbable implantable devices, and tissue engineering.
As a flexible external cell culture unit, CCS Cell Culture Service supplies the starting material for advanced screening and other research making HTS faster and more efficient, being a valid alternative to using cells from a continuous growing culture. CCS offers completely custom services in recombinant cell line generation, expressing your target of interest, and develops reliable and significant assays. All services are also tested for peak functionality as well as quality before shipment.
CCS also provides services in custom membrane preparations and recombinant proteins. Being one of the first providers of frozen cells, CCS offers our frozen cells in vials or in either 96 or 384 well plates, which can be stored in a -80°C freezer for up to 6 months and can be thawed for instant use in cell-based assays.
Columbia Laboratories is leveraging its rich heritage as a pharmaceutical research and development organization to become a leading women’s healthcare company. We will achieve this goal by increasing market share of our current products while developing new products for Columbia and our strategic partners.
Cyclacel Pharmaceuticals is a biopharmaceutical company dedicated to the discovery, development, and commercialization of novel drugs to treat human cancers and other serious disorders. The company’s strategy is to build a diversified biopharmaceutical business based on a portfolio of commercial products and a development pipeline of novel drug candidates.
Drais Pharmaceuticals, Inc., is an ethical pharmaceutical company dedicated to the development of novel therapeutic treatments that address unmet medical needs and provide significant benefits over currently available therapies. The company consists of highly experienced, seasoned individuals with sustained, successful track records in the pharmaceutical industry.
Elusys Therapeutics is a privately held biopharmaceutical company focused on the development of antibody-based therapies for the treatment of infectious disease. The company has pioneered the development of a rapid injection, therapeutic antibody, Anthim™, for the treatment of anthrax infection following a biowarfare attack.
Endo Pharmaceuticals Cranbury (formerly Indevus) is a subsidiary of Endo Pharmaceuticals Inc. We occupy approximately 50,000 square feet of manufacturing, laboratory and office space in New Jersey, where we manufacture two products, Vantas® and Supprelin®LA, and support development of additional drugs based around proprietary polymer implant technology.
HSP USA is a privately held biotechnology company that provides innovative clean technology for disinfection, water treatment and purification, environmental control and cleansing for industrial, commercial, and healthcare applications. Our main products are SteriMixer machines and Hsp2O hospital-grade disinfectant.
MannKind Corporation is a biopharmaceutical company that focuses on the discovery, development, and commercialization of therapeutic products for diseases, such as diabetes and cancer. The company’s lead investigational product candidate, AFRESA®, is an ultra rapid-acting insulin drug.
Neurotez, Inc., utilizes an integrated platform from discovery to proof of concept clinical trials for CNS drugs that are both safe and efficacious. We are dedicated to excellence, improving lives, and serving the public responsibly.
NPS Pharmaceuticals develops specialty therapeutics for gastrointestinal and endocrine disorders, such as its two late-stage registration studies for intestinal failure associated with short bowel syndrome and hormone replacement therapy for hypoparathyroidism.
PanOptica, Inc., is a private biopharmaceutical company focused on licensing and developing innovative ophthalmology therapies. The company was founded in March 2009 by co-founders Paul Chaney, past president of OSI Eyetech, and Martin Wax, MD, who formerly headed Pharmaceutical R&D at Alcon.
In December 2010, PanOptica, Inc., raised $30 million in a Series A financing led by SV Life Sciences and Third Rock Ventures. The completion of this financing coincides with the company’s successful licensing of exclusive worldwide ophthalmic rights to PAN-90806 from OSI Pharmaceuticals, Inc., a wholly owned subsidiary of Astellas US Holding, Inc., for the treatment for neovascular age-related macular degeneration, also known as wet AMD.
Pharmasset, Inc., is a clinical-stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections. Our primary focus is on the development of oral therapeutics for the treatment of hepatitis C virus (“HCV”). Additionally, we are continuing to identify the best path forward for the development of Racivir, for the treatment of HIV following the completion of a Phase 2 clinical trial. Our research and development efforts focus on a class of compounds known as nucleoside analogs, which act to inhibit the enzymes required for viral replication. We are applying our expertise in nucleoside chemistry to the discovery and development of additional antiviral therapeutics for HCV.
Pipeline Biotechnology was founded in 2007 by a group of medical device industry veterans. The company’s entrepreneurial management team comprises highly experienced individuals with a proven track record for success. Pipeline is a company that identifies and brings to market novel medical products and technologies. In addition, Pipeline is capable of evaluating, capitalizing, and managing businesses that possess novel intellectual property and products. Pipeline Biotechnology is actively reviewing potential technologies in market segments that include medical implants, operating room equipment, surgical instruments, and diagnostics. Technologies, products, and ideas are developed in-house and through partnering with external sources such as universities, venture-capital firms, medical institutions, companies, and inventors.
Regado Biosciences is pioneering a new therapeutic technology with the creation and development of two-component antithrombotic drug systems. Each system comprises a nuclease-stabilized RNA aptamer that can be controlled directly by its specific and complementary oligonucleotide active control agent. Regado’s technology is designed to give physicians the ability to actively and directly control each system’s therapeutic effect, providing a safe and unique approach to personalized medicine.
Senesco Technologies, Inc., (NYSE Amex: SNT) is a cancer therapeutics company leveraging its strong proprietary position in eukaryotic translation initiation Factor 5A (eIF5A) technology to regulate programmed cell death, also known as apoptosis. eIF5A modulation has been effective in all human cancer cells tested so far and against human multiple myeloma tumors in animal models. The company is preparing to initiate a clinical program in multiple myeloma patients with its lead therapeutic candidate SNS01-T. SNS01-T incorporates recent developments in siRNA, DNA regulation, and nanotechnology. Senesco is building its portfolio with other potential eiF5A applications in cancer, inflammation, and ischemia. For more information, visit our website or contact Les Browne at (908) 864-4444.
Soligenix, Inc., formerly known as DOR BioPharma, Inc., is a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. Soligenix’s lead product, orBec® (oral beclomethasone dipropionate or BDP), is a potent, locally acting corticosteroid being developed for the treatment of GI GVHD.
Sophion provides advanced products and integrated solutions for automated patch clamping. Sophion’s unique QPatch has an integrated cell preparation and QPlate exchange facilities enabling several hours of unattended operation. The flow channel system implemented in the QPlates enables fast liquid exchange around each cell and provides the option to test multiple compounds or increasing concentrations on the same cell. The new 48-channel QPatch HTX takes automated patch clamping to an even more powerful level. With its ability to generate thousands of high-quality data points daily, QPatch HTX enables new screening paradigms in ion channel drug discovery and safety testing.
Tactical Therapeutics, Inc. (“Tactical”) is a virtual biopharma company located in New York City. Tactical’s platform technology involves development of safer and deliverable small molecules by chemical restructuring of drugs. Currently Tactical is testing its lead multi-targeted drug, CTO, in Phase I and IIA exploratory trials in glioblastoma multiforme. The strategy of using a combination of CTO (P13K/MAPK/VEGF/Ca signal inhibitor) and approved cytotoxic agents has more than additive effects in preclinical models on efficacy and overall survival. Tactical intends to develop this strategy for more solid tumors (melanoma, thyroid, pediatric, GBM, etc.) based on a personalized and translational medical approach.
Thymon, LLC, founded in 1996 by Dr. Gideon Goldstein, functions as a virtual company with all laboratory and clinical studies directed and funded internally but performed externally by contracted organizations.
The company is the assignee of seven issued Goldstein patents covering a synthetic universal HIV-1 Tat epitope vaccine (TUTI-16) and a human monoclonal antibody (tepiumab) universally reactive with HIV-1 Tat protein.
HIV-1 Tat protein is essential for maintenance of HIV set point viremia, and an exploratory randomized, placebo-controlled study of TUTI-16 in untreated HIV-infected subjects yielded a highly significant reduction in viral load following immunization.
This study supported the feasibility of TUTI-16 as a potential prophylactic and therapeutic HIV/AIDS vaccine and the feasibility of tepiumab for antiretroviral treatment.
Thymon will be seeking licensing partner(s) as these projects move towards BLA studies and commercialization.
VaxInnate is a privately held biotechnology company that is pioneering breakthrough technology for use in developing novel, proprietary vaccines. Now in clinical development, this novel technology has the potential to dramatically improve the potency, manufacturing capacity, and cost-effectiveness of vaccines.
BioNJ thanks our Core Members who have renewed their Memberships for 2011.
MannKind Corporation is a biopharmaceutical company that focuses on the discovery, development, and commercialization of therapeutic products for diseases, such as diabetes and cancer. The company’s lead investigational product candidate, AFRESA®, is an ultra rapid-acting insulin drug.
Novartis Pharmaceuticals Corporation (NPC) researches, develops, manufactures, and markets leading innovative prescription drugs used to treat a number of diseases and conditions, including central nervous system disorders, organ transplantation, cardiovascular diseases, dermatological disorders, respiratory disorders, cancer, and arthritis.
BioNJ thanks our Associate Members who have renewed their memberships for 2012.
Auld Consulting LLC
Finding someone who understands the Human Resources issues specific to the biotech and pharmaceutical industry can be difficult, especially for small and start-up companies with tight budgets. Auld Consulting LLC is their HR department or assists existing staff as needed. With Auld Consulting, companies have access to an expert without the expense of a staff member.
Berkley Life Sciences is a wholly owned subsidiary of W. R. Berkley Corporation. We offer an array of property and casualty insurance products designed for the Life Sciences industry. We are the only insurance company focusing solely on insuring those in the Life Sciences field. Berkley Life Sciences offers its products and services through select retail and wholesale distribution channels. W. R. Berkley Corporation is one of the nation’s premier commercial lines property casualty insurance providers.
BioConsulting International, LLC (BCI) is well positioned to provide your organization with practical answers to the myriad of complex problems that arise in life science, in vitro diagnostic, and biotech business operations during periods of rapid growth. Whether those problems or challenges present themselves in the Development, Manufacturing, or Quality facets of a project, or whether external factors may be in play, the sole focus of our service is to quickly assess the particular client business situation, and recommend immediate and mid-term solutions that are custom-fit to the organization’s capabilities. We work with small and medium-sized firms on a variety of projects that span a range of operational, technical, and compliance-based issues.
BCI provides a unique and focused set of capabilities tailored for the life sciences or IVD client who is looking to start or build up their business and who prefer to work with a small, focused, and experienced consulting entity to achieve their goals. BCI operates primarily on a project fee consulting basis, but arrangements can also be developed to include retainer, per-diem, or hourly based consults. We seek to provide the most flexible arrangement that is customized to effectively deliver the results required for each client and project.
BioPharm Associates is a project management company whose focus is on improving business results and value for corporations. The company develops the skills and managerial attention needed to create business success for biopharmaceutical corporations across the globe.
Business Wire is the global market leader in commercial news distribution with thousands of member companies and organizations depending on it to transmit their full-text news releases, regulatory filings, photos, and other multimedia content to journalists, financial professionals, investor services, regulatory authorities, and the general public worldwide.
Defined Health is a business-strategy consulting firm. Client base is a mix of big pharma, emerging and specialty pharma, biotech, and healthcare investment companies. Services include opportunity assessments, therapeutic area growth strategies, and identification and evaluation of partnering opportunities.
Founded in 1985, Domain Associates, LLC is a venture-capital firm with an exclusive focus on life sciences. With $2.5 billion of capital under management, Domain has offices in Princeton, NJ, and San Diego, CA. Domain’s three major investment segments are pharmaceuticals, specialty pharmaceuticals, and medical devices, while additional areas of interest include biomaterials, bioinstrumentation, and diagnostics. The Partners of Domain have a total of close to 200 person-years of experience among them in the healthcare/venture-capital industries and have been involved in the formation and growth of more than 210 life-sciences companies. For further information, visit our website.
Franzwa Real Estate Advisors offer commercial real estate services and office tenant representation with a specialty in life sciences, lab, R&D, pilot plant, and manufacturing facilities. Leasing/Sales acquisitions and disposition services are also available. Franzwa Principal Mary Ryan placed BioNJ in its new headquarters.
Infinity Resources’ mission is to assist our clients in their growth through providing the highest caliber candidates who can drive the process within an organization. Each organization is unique in its culture, philosophies, and market needs. All cannot survive without their most important corporate asset — people. We provide the executive talent that drives your growth. Our rigorous process and industry knowledge, combined with the solid building blocks necessary for client, candidate, and internal relationships creates the basis for our success in servicing organizations.
Kayentis provides an innovative digital pen and paper solution for data capture in clinical trials. This approach combines the benefits of traditional pen and paper data capture – its simplicity, accuracy, and the ability to retain a source document – while providing all the benefits of electronic data capture, such as real time tracking and the ability to share data across multiple sites/users and to provide a full audit trail.
MD Becker Partners is a boutique management and strategy consulting firm focusing on both public and private companies in the life sciences industry. The firm integrates the three independent disciplines of investors and public relations, strategic advisory, and operational improvement and applies them to carefully conceived and expertly enacted strategies that help companies increase visibility, unlock stakeholder value, and access resources to grow their business. We serve a broad range of clients, ranging from emerging biotechnology and medical device companies to established pharmaceutical leaders. We also work directly with venture capitalists and institutional investors that provide capital to these companies.
Groupe Novasep offers products and services to the pharmaceutical, biotech, and industrial biotech markets. Novasep Process and Novasep Synthesis are highly complementary organizations with unique skills designed to provide technically optimized solutions for the life sciences and related industries.
Novasep Process provides solutions for process development and purification of final product from lab to turn-key industrial process using a range of techniques including batch and continuous chromatography techniques, cross flow membranes, and outsourcing manufacturing of biomolecules. Novasep Synthesis provides R&D and custom synthesis, from lab to industrial scale, with special expertise in hazardous chemistry, chiral chemistry, and Highly Potent APIs.
ProStrakan is an international pharmaceutical company based in Galashiels, Scotland, that focuses on developing prescription medicines for the treatment of unmet medical needs. In the United States, the company’s primary focus is the product areas of chemotherapy-induced nausea and vomiting, men’s health, and pain relief.
Scientific Search has been placing MDs, PhDs, Regulatory Affairs, Quality Assurance, Pre-Clinical and Clinical Development and Management, Pharmacovigilance, Toxicology, Engineering, Market Research, R&D, Information Technology, and related professionals at the technical, management, and executive levels since 1983. This includes significant work throughout the Mid-Atlantic region and the United States. Our firm has very extensive resources in terms of recruiters and most importantly biotechnology industry contacts who enable us to find the right people quickly. We fill full-time direct, as well as temporary, and temp-to-direct positions. Additional information is available at our website.
Twenty-first-century business realities, driven by enhanced productivity tools, increased competition, a volatile, rapidly changing economy, and the unique needs of and challenges confronted by clients, are creating paradigm shifts in the delivery of legal services. We created SorinRoyerCooper to reinvent law firm practice to address these issues, especially for clients in the emerging-growth and middle-market sectors, including technology, communications, internet, alternative energy, nanotechnology, and life sciences. We provide creative and sophisticated solutions characterized by the highest-quality lawyering and responsive service. Our counsel is imbued with a businessperson’s sensibility and offered at a common sense fee structure. As a result, we provide a compelling value proposition. SorinRoyerCooper comprises lawyers long recognized as practice and thought leaders in the service of emerging-growth and middle-market sector companies, and the investors, directors, and officers who serve them. We join our expertise, deep and broad experience, strict adherence to core values and principles, and results-oriented approach with a commitment to a low-cost infrastructure. By focusing on cost containment and employing a lower leverage model, we offer fees that are up to 50 percent less than those of our primary competitors. At the same time, we are deeply committed to employing the highest quality lawyers and offer compensation packages designed to attract the very best. Our rapidly growing roster of clients continues to demonstrate how well our alternative solution resonates with the business and investment communities.
SouthPoint Associates LLC was founded to assist life-sciences companies with business development, expansion, and financing needs. We support managements, boards of directors, and investors with objective perspectives on business development, due diligence, competitive analysis , technology transfer, strategic planning, and financing.
Located in historic Cranbury, NJ, Stone’s Throw, Inc., is a strategic copy-and-design team providing marketing consultation and creative services primarily to business-to-business clients. Client industries include healthcare, biotechnology and life sciences, pharmaceutical and pharmaceutical services, professional services, and education. Project types range from capabilities packages to thought-leadership paper development, from informational brochures and spec sheets to scientific posters, and from sales materials to website design and content. Founded in 1991. For more information and to view samples, visit our website or email or call Deanne Napurano at 609-395-0650.
BioNJ thanks our Associate Members who have renewed their Memberships for 2011.
HCRAmerica is a full-service, scientifically driven, Phase I-IV CRO based in Princeton and an affiliate of Harrison Clinical Research, GmbH, a global CRO with offices worldwide. Dr. Michael Willett joins HCRAmerica as President and brings a 20 year record as a successful senior executive, clinical scientist, and regulatory strategist. HCRAmerica is proud to be a member of BioNJ.
Korn/Ferry International, with a presence throughout the Americas, Asia Pacific, Europe, the Middle East, and Africa, is a premier global provider of talent management solutions celebrating 40 years in business. Based in Los Angeles, the firm delivers an array of solutions that help clients to attract, develop, retain, and sustain their talent. Korn/Ferry’s Global Life Sciences and Healthcare Services practice leads the marketplace in number of engagements within the industry, having conducted more than 4,000 searches worldwide in the last 4 years. Visit our website for more information on the Korn/Ferry International family of companies, and Korn/Ferry Institute for thought leadership, intellectual property and research.
Pharm-Olam International is a multinational contract clinical research organization offering full-service, clinical research services to the pharmaceutical, biotechnology, and medical device industries.